Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 1 1

Status

Completed 2Withdrawn 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Myeloid 3

Conditions

Primary Myelofibrosis 9Leukemia 7Myeloproliferative Disorders 6Polycythemia Vera 4Leukemia, Myeloid, Acute 4Thrombocytosis 3Thrombocythemia, Essential 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic Syndromes 3Multiple Myeloma 3Breast Neoplasms 3Prostatic Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic-Myeloproliferative Diseases 2Lymphoma 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hematologic Diseases 2Carcinoma, Non-Small-Cell Lung 2Bone Marrow Diseases 2Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Disorder 1Recurrence 1Preleukemia 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Peripheral Blood Stem Cell Transplantation 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1

Interventions

ruxolitinib 3venetoclax 1sonidegib 1pevonedistat 1pelcitoclax 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Thrombocytosis × ruxolitinib × Clear all
NCT04354727 2022-07-12

A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy

Ascentage Pharma Group Inc.

Phase 1/2 Withdrawn
Myeloid

Polycythemia Vera, Thrombocytosis, Primary Myelofibrosis

NCT01787552 2020-04-15

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

Novartis

Phase 1/2 Completed
50 enrolled 23 charts
Myeloid

Blood Coagulation Disorders, Blood Platelet Disorders, Bone Marrow Diseases, Hematologic Diseases, Hemorrhagic Disorders, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Thrombocytosis, Primary Myelofibrosis

NCT00509899 2018-03-12

Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis

Incyte Corporation

Phase 1/2 Completed
154 enrolled 26 charts
Myeloid

Polycythemia Vera, Thrombocytosis, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡